BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 23236426)

  • 1. The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.
    Xiang B; Zhang G; Ren H; Sunkara M; Morris AJ; Gartner TK; Smyth SS; Li Z
    PLoS One; 2012; 7(12):e51037. PubMed ID: 23236426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
    Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
    Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.
    Srinivasan S; Mir F; Huang JS; Khasawneh FT; Lam SC; Le Breton GC
    J Biol Chem; 2009 Jun; 284(24):16108-16117. PubMed ID: 19346255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
    Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
    Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin by activation of adenosine A
    Rukoyatkina N; Shpakova V; Bogoutdinova A; Kharazova A; Mindukshev I; Gambaryan S
    Biochem Biophys Res Commun; 2022 Jan; 586():20-26. PubMed ID: 34823218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
    Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
    J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
    Kobsar AL; Koessler J; Rajkovic MS; Brunner KP; Steigerwald U; Walter U
    Platelets; 2010; 21(2):112-6. PubMed ID: 20085435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12.
    Zhang Y; Ye J; Hu L; Zhang S; Zhang SH; Li Y; Kunapuli SP; Ding Z
    J Thromb Haemost; 2012 Oct; 10(10):2149-57. PubMed ID: 22906019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin.
    Cattaneo M; Lecchi A
    J Thromb Haemost; 2007 Mar; 5(3):577-82. PubMed ID: 17155953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet effects of caffeic acid due to Ca(2+) mobilizationinhibition via cAMP-dependent inositol-1, 4, 5-trisphosphate receptor phosphorylation.
    Lee DH; Kim HH; Cho HJ; Bae JS; Yu YB; Park HJ
    J Atheroscler Thromb; 2014; 21(1):23-37. PubMed ID: 24088646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the antiplatelet effects of cangrelor be reliably studied in mice under in vivo and in vitro conditions using flow cytometry?
    Kassassir H; Siewiera K; Sychowski R; Watała C
    Pharmacol Rep; 2013; 65(4):870-83. PubMed ID: 24145081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.
    Bijak M; Szelenberger R; Dziedzic A; Saluk-Bijak J
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29439388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia Modulates Platelet Purinergic Signalling Pathways.
    Paterson GG; Young JM; Willson JA; Graham CJ; Dru RC; Lee EW; Torpey GS; Walmsley SR; Chan MV; Warner TD; Baillie JK; Thompson AAR
    Thromb Haemost; 2020 Feb; 120(2):253-261. PubMed ID: 31858521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelets Express Activated P2Y
    Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z
    Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cangrelor attenuates coated-platelet formation.
    Norgard NB; Hann CL; Dale GL
    Clin Appl Thromb Hemost; 2009; 15(2):177-82. PubMed ID: 18796456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
    Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF
    Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ginsenoside-Rp3 inhibits platelet activation and thrombus formation by regulating MAPK and cyclic nucleotide signaling.
    Irfan M; Jeong D; Kwon HW; Shin JH; Park SJ; Kwak D; Kim TH; Lee DH; Park HJ; Rhee MH
    Vascul Pharmacol; 2018 Oct; 109():45-55. PubMed ID: 29890296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of platelet sensitivity to inhibitors of COX-1, P2Y₁, and P2Y₁₂ using a whole blood microfluidic flow assay.
    Li R; Diamond SL
    Thromb Res; 2014 Feb; 133(2):203-10. PubMed ID: 24365044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.